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NOVEL CHARACTERISTICS OF MLRINE BONE MARROW-DERIVED
MACROPHAGES AND HUMAN MACROPHAGE-LIKE CELLS
George T. Georges, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2006
Major Director: Jennifer K Stewart, Ph.D., Associate Professor, Department of Biology

These studies provide evidence for novel properties of macrophages derived from
bone marrow stem cells. In study 1, treatment of activated mouse bone marrow-derived
macrophages (BMM) with either catecholamine synthesis inhibitors (a-methyl-paratyrosine and fusaric acid) or the

p2 adrenergic receptor antagonist ICI 118,551

demonstrated that BMM produce catecl~olamines.The catecholamines modulated
macrophage cytolune production through autocrine actions on adrenergic receptors. In
study 11, undifferentiated human bone marrow cells were incubated in 30% mouse L929
fibroblast conditioned medium and generated adherent cells within three days. The cells
were clearly identifiable as macrophages based on surface proteins and phagocytic
activity but produced only low levels of the cytokines tumor necrosis factor-a and
interleulun-lp. Cytolune production did not increase in response to the bacterial
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endotoxin lipopolysaccharide (LPS). Generation of these macrophage-like cells was not
repeatable with other samples of human bone marrow, but the cells continue to proliferate
in cell culture and will be investigated further in future studies.

Study 1
Synthesis and Autocrine Actions of Catecholamines in Mouse
Bone Marrow-Derived Macrophages

Introduction

Macrophages are a critical part of the innate immune response of host defense.
Upon entering the body, bacteria and other foreign antigens are identified by the cells of
the immune system, which act quickly to eliminate them. Macrophages are characterized
by their ability to become activated in the presence of the foreign antigen. Activation
stimulates macrophages to engulf particles by phagocytosis and to produce cytolunes that
are important immune regulators.
Macrophages are derived from the pluripotent hematopoeitic bone marrow stem
cells. The process of differentiation requires chemical signals that allow the cells to
develop along a specific cell lineage. In the case of macrophages, macrophage-colony
stimulating factor (M-CSF) and granulocyte macrophage-colony stimulating factor (GMCSF) are required to commit the cells to the myeloid cell lineage (17). The stem cells first
develop into monocytes in the blood, whereby further development through continued
stimulation results in the formation of localized, tissue-specific macrophages.
Macrophages are known to express a2 and pz adrenergic receptors that enable the
catecholamines, norepinephrine and epinephrine, to modulate cytolune production and
influence immune function. Previous studies have demonstrated that binding of
catecholamines or other adrenergic agonists to

pz adrenergic receptors inhibits

macrophage production of tumor necrosis factor-a (TNF- a) and interleulun-1P (IL-1P)
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(3; 11; 12; 16; 21; 22). Binding to a2 adrenergic receptors stimulates production of these
cytokines (5; 6; 22; 23).
Although catecholamines are produced primarily by neurons and the adrenal
medulla, macrophages have been reported to take up catecholamines from extracellar
fluids (1; 13), and catecholamines have been measured in peritoneal macrophages by two
laboratories (15; 22). Scott Brown in our laboratory detected tyrosine hydroxylase (TH)
mRNA, the rate limiting enzyme of the catecholamine synthesis pathway, in the
RAW264.7 macrophage cell line following treatment with the bacterial endotoxin,
lipopolysaccharide (LPS) (2). TH mRNA increased three fold from 24 h to 48 h after LPS
treatment. In the same study, both intracellular and extracellular norepinephrine levels
decreased in the presence of a-methyl-para-tyrosine (a-mpt), which prevents the activity
of TH. These findings suggest that catecholamines are synthesized in RAW264.7
macrophages.
It is unclear whether catecholamines in primary macrophages are synthesized by
these cells or taken up and stored for subsequent release. Several studies suggest that
macrophages release norepinephrine. For example, our laboratory demonstrated that the
RAW264.7 macrophage cell line releases norepinephrine (2), and Miller and colleagues
found that human synovial macrophages release norepinephrine (19). Spengler and
colleagues reported that intracellular levels of norepinephrine in peritoneal macrophages
are reduced 30 minutes after the cells are stimulated with LPS (22), suggesting that
intracellular catecholamines are released from macrophages into the extracellular
environment upon stimulation. Additionally, there is evidence that macrophage

production of cytokines is modulated by autocrine actions of macrophage-derived
catecholamines binding adrenergic receptors. For example, treatment of peritoneal
macrophages with adrenergic receptor antagonists (in the absence of exogenous
catecholamines) modulates LPS stimulated production of the cytolunes tumor necrosis
factor-alpha (TNF-a) (22) and interleukn- 1p (IL- 1P) (7).
Although it is now clear that mouse peritoneal macrophages release
catecholamines that exert autocrine effects on cytokne production, it is not known if this
regulatory mechanism is present in newly differentiated murine bone marrow-derived
macrophages. This question is important because bone marrow stem cells from
experimental animals and human subjects are important precursors of macrophages, and
these cells are often the major source of macrophages used for research. The focus of this
study is to investigate whether mouse BMM synthesize catecholamines and whether
catecholamines released by these cells display the same autocrine regulation of cytoknes
through the adrenergic receptors as is seen in mouse peritoneal macrophages.

Methods and Materials

Cells
Female CBAIJ mice (6-8 weeks of age) were obtained from Harlan (Indianapolis,
IN), and 6 month old female C57BL6Jl129 mice were obtained from Tachonic
(Germantown, NY). Mice were euthanized with COz. Cells were collected from tibia and
femurs (4) and washed with complete RPMI (cRPMI) medium consisting of RPMI 1640
(Invitrogen) supplemented with 10% heat inactivated-FBS, 1% L-glutamine, 1% nonessential amino acids, 1% minimal essential medium vitamins, 100 unitslml penicillin
and 100 pglml streptomycin. The cells were seeded in tissue culture plates in fresh
cRPMI with 30% L929-cell conditioned medium (a source of macrophage colony
stimulating factor) (8; 18). Cells were incubated at 37 "C in a humidified 5% C 0 2
atmosphere. After 24 hours, non-adherent cells were transferred to new 6 well tissue
culture-treated plates to eliminate any early adherent cells such as fibroblasts. After 1
week numerous adherent cells were evident, and the medium was replaced with fresh
30% L-cell/70% cRPMI. The adherent cells were identified with a macrophage surface
antigen and used in experiments the same week.

Two cell lines, L929 mouse fibroblasts, and RAW264.7 macrophages were
obtained from American Type Cell Culture (Manassas, VA). The cells were maintained
in cRPMI in 75 cm2tissue culture flasks. Stock cultures of L929 cells were sub-cultured
weekly, and RAW264.7 cells were sub-cultured twice weekly. For collection of L929
conditioned medium, approximately 200,000 L929 cells were seeded in 75 cm2 flasks in
25 ml of cRPMI. Medium was removed after one week, and fresh cRPMI was added. The
cells were maintained for a second week; then medium was again harvested, and cells
were discarded. The media samples were centrifuged at 500 x g and 4 "C for 10 minutes,
and filtered with either 0.22 pm PVDF-syringe filters (Fisher Scientific) or Steriflip
vacuums filters with 0.22 pm PVDF membranes (Millipore Corporation, Billerica, MA),
and stored frozen at -20 "C in polypropylene tubes.
Bone marrow-derived mast cells were obtained from Mohit Kashyap in the
laboratory of Dr. John Ryan, Virginia Commonwealth University. Mast cells were
differentiated and maintained as previously described (9).

Identification of Macrophages with F4/80
F4180 is a surface antigen expressed by mature macrophages. Compared with
other commonly used markers that are found on both fibroblasts and macrophages, F4/80
is more specific for macrophages (14). For F4180 detection, cells were washed with fresh
cRPMI medium and adjusted to 0.5x106cells/ml.An aliquot (180 p1) of the cells was
added to a 96 well v-bottom plate, washed with phosphate buffered saline (PBS), and
incubated with 10 pl of ascites 2.462 for 10 min to prevent non-specific binding to Fc-I1
and Fc-I11 receptors. Samples were incubated with phycoerythrine (PE)-labeled anti-

mouse F4180 antibody (eBioscience, San Diego, CA) at 2 pglml final concentration,
while control samples were incubated with PE Rat IgG2a isotype control (eBioscience,
San Diego, CA) at 20 pllwell. Following a 30 minute incubation, the wells were washed,
and cells binding the labeled antibody were detected with a BD FACS Calibur flow
cytometer. Results were analyzed with the BD CellQuest Pro software. Mouse mast cells
and RAW264.7 macrophages were assayed as negative and positive controls,
respectively.
Effects of catecholamine synthesis inhibitors on LPS-stimulated IL-6 production

Adherent cells in a 6 well plate were rinsed and removed with 3 ml of 0.25%
(w/v) Trypsin

+ 0.53 mM EDTA. Fresh cRPMI was added to the cells, and 1 . 5 ~ 1 cells
0~

per well were plated in a 24 well tissue culture-treated plate. The cells were incubated for
4 h at 37°C in 5% C 0 2to allow for adherence. BMM were then washed twice with warm

(37°C) phosphate buffered saline, pH 7.4, and treated with 30 nglml LPS (E. coli serotype 055:B5, Sigma) and catecholamine synthesis inhibitors (either 2 mM a-mpt or
500 pM fusaric acid) in a final volume of 0.5 ml serum-free RPMI. a-mpt inhibits the
activity of tyrosine hydroxylase, which converts L-tyrosine to L-dopa, and fusaric acid
inhibits the activity of dopamine-P-hydroxylase, which converts dopamine to
norepinephrine (20) (Figure 1). The macrophage monolayer in each well was washed
with PBS, lysed in 150 p1 of lysis buffer (0.05 M Tris (pH 7.5), 0.3 M NaC1, 2 rnM
EDTA, 0.5% Triton X-100, 2.0 p d m l leupeptin, 1 pglml aprotinin and 0.2 mM
phenylmethylsulfonylflouoride), and then frozen at -20°C for future determination of
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total cellular protein with the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules,
CA) and read at 595 nm in the microplate spectrophotometer.

Effects of the

p2

adrenergic antagonists on LPS stimulated IL-IP production

Bone marrow cells were treated with 30 nglml LPS (E. coli -serotype 055:B5,
Sigma, St. Louis, MO) and 10 pM ICI 118,551 (p2antagonist, Tocris, Ellisville, MO) in a
final volume of 0.5 ml serum-free RPMI. Following a 24 h incubation, extracellular fluid
was removed, centrifuged at 500 x g for 10 min at 4OC and then frozen at -30°C for future
IL-1P assay. The macrophage monolayer in the wells was washed with PBS, lysed in 150
yl lysis buffer as described above, and then frozen at -20 OC for future determination of
total cellular protein with the Bio-Rad protein assay.

Measurement of IL-6 and IL-IP
Extracellular cytokine concentrations were assayed with an OptEIA Multi
Component Elisa Set for Mouse IL-6 and a set for IL-113 (BD Biosciences, San Diego,
CA) in accordance with the nlanufacturer's instructions. The plate was read at 450 and
570 nm with a pQuant Universal Microplate Spectrophotometer (Bio-Tek Instruments,
Winooski, VT). Concentrations were calculated with the manufacturer's KC4 software.
Statistical analysis of all data was performed with GraphPad Prism, version 4.02.

Results

Verification of macrophage phenotype
Approximately 50% of the bone marrow-derived cells began to show adherence
on day two of incubation following marrow extraction. By day 4, nearly 80% of the cells
in each flask were healthy differentiated adherent cells with defined pseudopodia. The
cells displayed a high fluorescence intensity for the mature macrophage marker F4180,
and the expression of F4180 in the BMM was similar to that of the positive control (RAW
264.7 macrophage cells) (Figure 2).

EfSects of catecholamine synthesis inhibitors on IL-6 release
Catecholamine synthesis inhibitors significantly reduced extracellular levels of
IL-6. When treated with LPS + the tyrosine hydroxylase inhibitor a-mpt, extracellular IL6 decreased three fold when compared with LPS treatment alone (Figure 3). When the
BMM were treated with LPS + fusaric acid, an inhibitor of dopamine-P-hydroxylase,
similar results were observed (Figure 4). These findings suggests that mouse BMM
synthesize catecholamines that exert autocrine effects on the release of IL-6.
Furthermore, because fusaric acid inhibits synthesis of norepinephrine and epinephrine,
but not doparnine (Figure 2), the results suggest that IL-6 release is stimulated by BMMderived norepinephrine or epinephrine.

Autocrine actions of macrophage-derived catecholamines on IL-lp release
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When the BMM were treated with 30 nglml LPS and the P2-adrenergic receptor
antagonist ICI, the extracellular IL-1P levels increased two fold over those observed with
LPS alone (Figure 5 ) suggesting that

P2 adrenergic agonists released by BMM inhibit

LPS-stimulated production of IL-1 P. These results parallel those previously observed
with peritoneal macrophages (7) and suggest that BMM-derived catecholarnines display
an autocrine effect on IL- 1P mediated through the P2-adrenergic receptor.

Discussion

This study is the first to demonstrate that newly differentiated bone marrowderived macrophages (BMM) produce catecholamines, which modulate extracellular
levels of IL-1P and IL-6 produced by the macrophages. The autocrine actions of
catecholamines on the P2-adrenergic receptor in BMM are consistent with the results of
previous studies on peritoneal macrophages (7). Further investigation is needed to
determine whether BMM express the w2-adrenergic receptor and to determine the
receptor mediating autocrine effects of BMM-derived catecholamines on release of IL-6.
These findings are important for our understanding of regulatory mechanisms in BMM
and because BMM are frequently used to study macrophage functions.

.methyl-para-tyrosine

Tyrosine hydroxylase (TH)

L-DOPA

n

Aromatic amino acid
decarboxylase

Dopamine
Fusaric Acid

Dopamine P-hydroxylase (DBH)

Norepinephrine
Phenylethanolamine Nmethyltransferase (PNMT)

Epinephrine

Figure 1. Catecholamine synthesis pathway. a-methyl-para-tryosine inhibits the actions
of tyrosine hydroxylase (TH), preventing the synthesis of L-DOPA, dopamine,
norepinephrine, and epinephrine. Fusaric acid inhibits the actions of Dopamine Phydroxylase (DBH), preventing the synthesis of norepinephrine and epinephrine only.

Fluorescence Intensity

-

Figure 1: Expression of F4180 in mouse BMM. The shaded regions indicate non-specific
background staining, and lines represent triplicate samples with F4180 staining. (a) The
RAW 264.7 macrophage cells were a positive control. (b) Mast cells, a negative control,
showed no significant expression of F4180. (c) The F4180 staining of bone marrowderived cells was comparable to that of the positive controls cells.

Vehicle

LPS

LPS + a-mpt

Vehicle

LPS

LPS + a-mpt

Figure 3: Bone marrow derived macrophages were treated with LPS and the
catecholamine synthesis inhibitor a-methyl-para-tyrosine (a-mpt). a) Extracellular IL-6
was measured to determine the effects of catecholamine synthesis on mouse BMM
cytokine release. b) Protein levels were not different among treatment groups.
* P < 0.001 compared to LPS alone.

Vehicle
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-r
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Figure 4: Bone marrow derived macrophages were treated with LPS and the
catecholamine synthesis inhibitor fusaric acid. (a) Extracellular IL-6 was measured to
determine the effects of norepinephrine and epinephrine synthesis on mouse BMM
cytolune release. (b) The concentration of protein in each treatment group did not differ
significantly. * P < 0.001 compared to LPS alone.

Vehicle

LPS

LPS + ICI

Figure 5: Adrenergic receptor antagonists modulate LPS-stimulated release of IL-1P in
BMM. Murine BMM were treated with LPS and 10 pM ICI 118,551 (ICI) (P2 adrenergic
receptor antagonist) for 24 hrs. IL-1P was measured with a BD ELISA IOt. LPS
significantly stimulated the production of IL-lP, while the addition of ICI further
increased extracellular levels of IL-1P. * P < 0.01 compared to LPS alone.

Study 2
Differentiation and Characterization of Human Bone Marrow-Derived
Macrophage-Like Cells

Introduction
Hematopoiesis is the critical process of bone marrow stem cell development.
Undifferentiated cells derived from the bone marrow have the potential to become one of
many mature specialized cell components of blood. The process of cell differentiation is
mediated through a cell signaling mechanism involving the actions of specific cytolunes
and growth factors. In the case of macrophages, hematopoietic stem cells respond to
macrophage-colony stimulating factor (M-CSF) and granulocyte macrophage-colony
stimulating factor (GM-CSF)(8; 17). M-CSF is a survival, growth, differentiation, and
activating factor for macrophages and their progenitor cells. In the presence of these
cytokines, the cells commit to the myeloid cell lineage. These premature cells known as
monocytes are directed into the blood circulation where they continue their development
into macrophages under the continued influence of these cytokines. Interleukin-6 (IL-6)
is a cytokine produced by several types of cells including fibroblasts and is also important
in macrophage development (10).
L929 cells are a mouse fibroblast cell line known for continuous production of MCSF and IL-6. Studies have shown that macrophages differentiate from mouse femurderived stem cells when grown in L929 conditioned medium (4). These mouse bonemarrow derived macrophages have been the subject of several ongoing experiments
within our laboratory, and we were interested in continuing this research with human
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bone marrow-derived macrophages. Although investigators recently discovered a human
cell line that produces factors needed for human macrophage differentiation (lo), this cell
line is not available. Treating human stem cells with L929-conditioned medium did not
seem feasible because mouse derived M-CSF and IL-6 are documented as not displaying
cross-reactivity with human cytokine receptors (8) Nevertheless, we could find no
evidence that mouse L929 medium has ever been tested on human cells. It is known that
native cytokine proteins found in conditioned medium may differ in biological activity
from the recombinant proteins often used to test for cross reactivity (18). Also,
conditioned medium may contain unidentified factors that affect growth and
differentiation.
In this study, the effects of mouse L929 fibroblast conditioned medium on
development of undifferentiated human bone marrow cells was investigated.

Methods and Materials
Cells
Human bone marrow cells (cat. # ABMOOI-1) were obtained from Stem Cell
Technologies (Berkeley, CA). Cells were washed with complete RPMI (cRPMI) medium
consisting of RPMI 1640 (Invitrogen) supplemented with 10% heat inactivated-FBS, 1% Lglutarnine, 1% non-essential amino acids, 1% minimal essential medium vitamins, 100 unitsiml
penicillin and 100 pgiml streptomycin. The cells were seeded into tissue culture plates in fresh
cRPMI with 30% L929-cell conditioned medium (a source of macrophage colony stimulating
factor)(4; 18). Cells were incubated at 37 T in a humidified 5% C 0 2 atmosphere for 1 week.
Adherent cells were visible within 4 days.
Mouse L929 fibroblasts and RAW264.7 macrophages were maintained as described in
Study 1. Human dermal fibroblasts were obtained through Dr. Dome Yager from the Plastic
Surgery Department, Medical College of Virginia at Virginia Commonwealth University. These
cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM, cat. # 30-2002) from
ATCC (Manassas, VA) supplemented with 10% heat inactivated-FBS and 100 pg/ml
streptomycin. HEPG2 cells were obtained through Dr. Qibing Zhou, Department of Chemistry at
Virginia Commonwealth University, and were maintained by Lin Zhang. All cells were
incubated at 37°C in a humidified 5% C 0 2atmosphere.
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Identification of Surface Markers with Flow Cytometry
Fibroblasts are a major contaminant in adherent cell cultures. They adhere to the surface
of flasks and resemble macrophages in shape and size. To address this concern, the adherent
bone marrow-derived cells were assayed with flow cytometry to detect cell specific surface
antigens for both macrophages and fibroblasts. Cells were washed and adjusted to 1 x 1 0 ~
cells/ml
cRPMI. In a v-bottom tissue culture-treated plate, 180 p1 of bone marrow cells were added to
each well, washed, and blocked with 10 p1 of 2.462 rat ascites for 10 minutes at 4OC. Samples
included positive and negative control cells. Cells were incubated with antibodies to surface
markers for 30 minute at 4 OC, then analyzed by flow cytometry (BD, Facs Calibur) with BD
CellQuest Pro software. Macrophage cell surface markers included Mac-1 (identified with 2
pglml (phycoerythrin) PE-anti-Mac-1, egiosciences) and F4/80 (identified with 2 pglml PE-antiF4/80, eBiosciences). The fibroblast marker AS02 (identified with 2 pglrnl l omouse anti-human
A S 0 2 and 10 pglml 2" PE-goat anti-mouse AS02, eBiosciences) was used to identify any
contaminating fibroblasts. For macrophage identification with Mac-1, cells were compared with
the mouse macrophage cell line RAW264.7, which were the positive control cells, and with the
mouse fibroblast L929 cell line that was used as a negative control. For macrophage
identification with F4180, RAW264.7 cells were positive controls, and human dermal fibroblasts
were negative control cells. For fibroblast identification, human dermal fibroblasts and HEPG2
hepatocytes were used as positive and negative controls respectively.

Phagocytosis Assay
Phagocytosis of bacteria was measured with the Vybrant Phagocytosis IQt (Invitrogen V6694). All cells, including adherent human bone marrow-derived cells, positive controls
cells/ml in
(RAW264.7) and negative controls (human dermal fibroblasts) were adjusted to 1 x 1 0 ~

cRPMI medium, and 150 pllwell were added to a 96 well plate. Cells were incubated for 1 h to
allow for adherence. Following incubation, the medium was replaced with E. coli fluorescein
(F1TC)-labeled BioParticle suspension, and the cells were then incubated for 2 h. The cells were
then washed, and any remaining extracellular fluorescence was immediately quenched with
trypan blue. Samples were read in a Wallac victor2 rnultilabel counter (Perkln Elmer) at settings
of 480 nm excitation and 520 nm emission.
Cells were also incubated separately with the FITC-labeled BioParticle suspension on
microscope slides for 2 h and mounted with Vectasheild mounting media. The cells were viewed
with an Opelco IX-70 fluorescent inverted phase contrast microscope (OPELCO, Dullas, VA).
Images were saved with the QCapture software (OPELCO) and adjusted for size with Arcsoft
Photoimpression software.
EfSects ($LPS and adrenergic antagonists on TNF-a & IL-lp

Bone marrow derived cells were scraped gently from tissue culture-treated flasks
0 ~ were added to each
(Corning brand, Fisher Scientific)(4), and for each treatment, 1 . 5 ~ 1 cells
well in a 24 well tissue culture-treated plate (Costar brand, Fisher Scientific) in 0.5 ml serumfree cRPMI. The cells were incubated for 4 h at 37 OC in 5% COz to allow cell adherence. The
cells were then washed twice with warm (37 "C) phosphate buffered saline, pH 7.4, treated with
30 nglml LPS (E. coli -serotype 055:B5, Sigma) and either 10 pM ICI (P2antagonist, ICI118,55 1, Tocris) or 5 pM Yohimbine (a2 antagonist, Sigma), all in a final volume of 0.5 ml
serum-free RPMI. Following a 24 h incubation, extracellular fluid was removed, centrifuged at
500 x g for 10 min at 4 OC and then frozen at -20 OC for future IL-1PI TNF-a assays. The cell
monolayers in the wells were washed with PBS, lysed in 150 p1 lysis buffer (0.05 M Tris (pH
7.5), 0.3 M NaC1, 2 mM EDTA, 0.5% Triton X, 2.0 pglml leupeptin, 1 pglml aprotinin and 0.2
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mM phenylmethylsulfonylflouoride), and then frozen at -20 "C for future determination of
total cellular protein.
Measurement of ZL-lp, TNF-a, and total cellular protein

Extracellular concentrations of IL-1P were assayed with the OptEIA Multi Component
Elisa Set for Mouse IL-1P (BD Biosciences, San Diego, CA). The assay was performed in
accordance with the manufacturer's instructions. The plate was read at 450 and 570 nm with a
pQuant Universal Microplate Spectropl~otometer(Bio-Tek Instruments, Winooski, VT), and
concentrations were calculated with the manufacturer's KC4 software. Cell lysates were assayed
for total protein with the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA) and read
at 595 nm in the microplate reader.

Results
Identification of Cells
Identifying surface antigens that are specific for macrophages was an important initial
step in characterizing the human bone marrow-derived cells. The first of these surface markers
identified was MAC-1. When analyzed with flow cytometry, the MAC-1 surface antigen was
identified on all of the cells, including the negative control cells (L929 fibroblasts), indicating
that it was not a specific indicator of macrophages (Figure 1). The F4180 surface antigen showed
a higher degree of specificity for macrophages (Figure 2) (14). Compared with the positive and
negative controls, human bone marrow-derived cells exhibited a high fluorescence intensity for
F4180, indicating that these cells were similar to mature macrophages. When the cells were
examined for AS02, a fibroblast specific surface marker, the bone marrow-derived cells
exhibited low fluorescence intensity equaling the nonspecific fluorescence (Figure 3). Human
dermal fibroblasts (positive control) exhibited a high fluorescence intensity for AS02 as
expected. This result suggests that the bone marrow-derived cells are not fibroblasts.

Phagocytosis
The phagocytosis assay revealed that the human bone marrow-derived cells are
phagocytic (Figure 4). They cells engulfed the bacteria with a little over half the efficiency of the
RAW macrophage cell line (positive control). Human dermal fibroblasts did not show any
phagocytic activity. This finding indicates that the cells not only express macrophage specific
surface antigens but also are phagocytic.

RAW macrophages that were incubated on slides with the fluorescent bioparticle
suspension (FITC-Bacteria) were viewed with fluorescence microscopy (Figure 5). Cells not
receiving the suspension were examined for background fluorescence. The RAW macrophages
did not show any significant background fluorescence, and phagocytosis of particles was evident
in cells treated with the FITC-Bacteria. Human bone marrow derived cells exhibited phagocytic
activity comparable to that exhibited with the RAW macrophage cell line and exhibited no
background fluorescence in the absence of the fluorescent bioparticle incubation (Figure 6). A
bright-field view of the slide without the fluorescent incubation confirmed the presence of the
cells when no fluorescence was evident.

Cytokine Production
The human bone marrow-derived cells did not produce cytolunes in a manner typical of
macrophages. Low concentrations of TNF-a were produced continuously but did not increase in
response to LPS stimulation. The constitutive release of TNF-a did not appear to be altered by
LPS in either a time or dose dependent pattern (Figure 7). Furthermore, the cells produced only
low concentrations of IL-1P (Figure 8). LPS and adrenergic antagonists known to modulate ILl p release (7; 22) also had no significant effect on extracellular levels of this cytolune.

Discussion
The human bone marrow-derived cells investigated in this study can be described as
macrophage-like cells, as they have been found to express macrophage specific surface antigens
and exhibit phagocytic activity. The cells do not, however, produce cytolunes in response to LPS
as would be expected of macrophages. This new cell line proliferates in culture in cRPMI
(without L929-conditioned medium) and reaches confluency within several days of seeding.
Further studies are needed to investigate the mechanisms regulating cytokine production in this
new cell line.
Newly differentiated monocytes require specific signals for continued development to
macrophages. It is unclear whether L929-conditioned medium provided the signals for the
human bone marrow cells to differentiate into macrophage-like cells or whether the cells were
transformed in vivo. Cytolunes such as M-CSF and L - 6 have been identified for their key roles
in macrophage differentiation. For example, IL-6 is reported to up-regulate M-CSF receptors on
the surface of macrophages (10). L929 fibroblasts produce mouse IL-6 and M-CSF, but it is
unclear whether these mouse cytolunes bound to receptors on the human cells. Also, it is
possible that other unidentified growth factors needed for normal mouse bone marrow cell
differentiation and development may not have cross reacted with receptors on human cells.
Because we were not able to repeat this study with human bone marrow cells incubated in L929conditioned medium, it is conceivable that the cells in this study were transformed to a
continuously proliferating cell line in vivo. The cells are easily maintained in culture and will be
used for future studies of macrophage-like functions.
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Figure 1: MAC-1 staining for macrophages. Shaded areas indicate background non-specific
staining. Lines represent duplicate samples. (a) RAW 264.7 macrophages stained for MAC-1
(positive control). (b) Mouse L929 fibroblasts, a negative control, also showed high fluorescence
for MAC-1 indicating that MAC-1 is not a macrophage-specific marker. (c) Human bone
marrow-derived cells also stained for MAC-1.
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Figure 2: F4180 (mature macrophage marker) staining. Shaded areas indicate background nonspecific staining. Lines represent triplicate samples. (a) The RAW 264.7 macrophage cell line
was stained as a positive control for this marker. (b) Human dermal fibroblasts showed no
specific staining. (c) Human bone marrow-derived cells were positive for F4180.
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Figure 3: A S 0 2 (fibroblast-specific surface marker) staining. Shaded areas indicate background
non-specific staining. Lines represent triplicate samples. (a) Human dermal fibroblasts, positive
control cells, stained for AS02. (b) A hepatocyte carcinoma cell line HEP-G2, negative control
cells, showed no staining for the fibroblast-specific protein. (c) The human bone marrow-derived
cells showed no staining for AS02.

Phagocytosis Assay

Figure 4: Phagocytic activity of human bone marrow-derived cells and control cells. Phagocytic
cells (RAW), non-phagocytic (human dermal fibroblasts) (FTBRO), and human bone-derived
cells were assayed in the absence of bacteria to account for background fluorescence or
incubated with fluorescein-labeled bacteria (FITC-BACT).

RAW macrophages
treated w l FITC-Bact.

-

Raw macrophages wlout
FITC-Bact. treatment

Figure 5: RAW 264.7 macrophages incubated with the fluorescent bioparticle suspension. (a)
High fluorescence of intracellular bacteria was observed with an inverted phase contrast
microscope. (b) Cells that were not incubated with fluorescent bacteria showed minimal to no
fluorescence, indicating that endogenous macrophage fluorescence is negligible.
Magnification = 400X

HUMAN CELLS
Top Left: Human Cells Treated w l FITC-Bact.
Top Right: Human Cells wlout FITC-Bact.
Bottom: Bright field view of human cells wlout
FICT-Bact.

Figure 6 : Cells treated with the fluorescent bacteria revealed a high level of phagocytosis
activity (top left). Cells that were incubated without the bacteria showed only minimal
background fluorescence as expected (top right). A bright field view (bottom right) of the cells
(top right) confirmed the presence of the bone marrow-derived cells on the slide.
Magnification = 400X

Figure 7: TNF-a production by the human macrophage-like cells following a 2,4, and 6 hour
incubation with 30 ng/ml LPS. Additionally, cells were treated for a 2 h incubation with 100
ng/ml LPS.

Figure 8: ILl-P production by the human macrophage-like cells assayed following a 24 h
incubation with LPS, LPS+ICI-118,551 (ICI), or LPS+Yohimbine (YOH). These bone marrowderived cells did not respond to LPS stimulation and produced little IL-1P.
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